www.akelapharma.com
Toronto Stock Exchange Symbol: AKL
MONTREAL, July 24 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that it has been awarded a contract at its
PharmaForm subsidiary located in Austin, Texas, to process validate and
manufacture Phase III Registration Batches for Proellex(R), a drug product
developed by Repros Therapeutics, Inc (NASDAQ: "RPRX").
"We are very pleased to have been awarded this important contract and
with our long relationship with Repros. Proellex(R) will fill unmet medical
needs and could be a blockbuster should it meet all clinical endpoints. It
represents a great partnership and opportunity for both organizations." said
Dr. Michael Crowley, Vice President, Business Development of PharmaForm.
About Repros:
Repros Therapeutics focuses on the development of oral small molecule
drugs for major unmet medical needs that treat male and female reproductive
disorders.
For more information, please visit the Company's website at
http://www.reprosrx.com.
About Akela Pharma Inc.:
Akela Pharma is an integrated drug development company focused on
developing therapies for the growing multi-billion dollar inhalation and pain
markets. Its lead product, for the treatment of breakthrough cancer pain, is a
fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry
powder inhaler platform. Its pipeline also includes therapeutics for asthma,
COPD, growth hormone deficiencies and controlled substance abuse deterrent
formulations. PharmaForm, Akela's wholly owned subsidiary, is a leading
specialty contract service provider offering a portfolio of innovative
technologies in drug product development, manufacturing and analytical testing
to the pharmaceutical and biotechnology industries. Through its diverse
offerings, PharmaForm solutions help clients reduce development costs and
accelerate time-to-market.
Akela's common shares trade on The Toronto Stock Exchange ("TSX") under
the symbol "AKL" with 21.6 million shares outstanding.
This news release contains certain forward-looking statements that
reflect the current views and/or expectations of Akela Pharma Inc. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly.
%SEDAR: 00003466EF
For further information: visit www.akelapharma.com or contact: Frédéric
Dumais, Vice-President, Investor Relations, (514) 315-3330 ext. 106, Fax:
(514) 315-3325
